These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

390 related items for PubMed ID: 22992238

  • 21. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.
    Rossbach HC.
    Vasc Health Risk Manag; 2010 Mar 03; 6():59-68. PubMed ID: 20234780
    [Abstract] [Full Text] [Related]

  • 22. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A, Kuwashima M, Nagao T.
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep 03; 45(5):987-92. PubMed ID: 6818811
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R, Kurnik K, Friedrichs F, Halimeh S, Krümpel A, Bidlingmaier C, Nowak-Göttl U.
    Thromb Haemost; 2008 Jan 03; 99(1):71-6. PubMed ID: 18217137
    [Abstract] [Full Text] [Related]

  • 29. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G, Lafeber FP.
    Ned Tijdschr Geneeskd; 2007 Nov 24; 151(47):2606-8. PubMed ID: 18161260
    [Abstract] [Full Text] [Related]

  • 30. Maintenance of treatment logs by haemophilia patients.
    du Treil S, Rice J, Leissinger CA.
    Haemophilia; 2010 May 24; 16(3):545-7. PubMed ID: 20050930
    [No Abstract] [Full Text] [Related]

  • 31. Sodium content in products used to treat haemophilia.
    Altisent C, Martorell M, de la Sierra A.
    Haemophilia; 2016 Jul 24; 22(4):e324-7. PubMed ID: 27228069
    [No Abstract] [Full Text] [Related]

  • 32. Defining adherence to prophylaxis in haemophilia.
    Schrijvers LH, Cnossen MH, Beijlevelt-Van der Zande M, Peters M, Schuurmans MJ, Fischer K.
    Haemophilia; 2016 Jul 24; 22(4):e311-4. PubMed ID: 27227699
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Recombinant factor VIII in hemophilia A: the Canadian experience.
    Blanchette VS.
    Blood Coagul Fibrinolysis; 1997 Aug 24; 8 Suppl 1():S33-9. PubMed ID: 9351535
    [Abstract] [Full Text] [Related]

  • 37. In vivo bypass of hemophilia A coagulation defect by factor XIIa implant.
    Ton-That TT, Doron D, Pollard BS, Bacher J, Pollard HB.
    Nat Biotechnol; 2000 Mar 24; 18(3):289-95. PubMed ID: 10700143
    [Abstract] [Full Text] [Related]

  • 38. New treatment for hemophilia.
    FDA Consum; 2003 Mar 24; 37(6):5. PubMed ID: 14983810
    [No Abstract] [Full Text] [Related]

  • 39. Coagulation factors with improved properties for hemophilia gene therapy.
    Pipe SW.
    Semin Thromb Hemost; 2004 Apr 24; 30(2):227-37. PubMed ID: 15118934
    [Abstract] [Full Text] [Related]

  • 40. Evolving Complexity in Hemophilia Management.
    Croteau SE.
    Pediatr Clin North Am; 2018 Jun 24; 65(3):407-425. PubMed ID: 29803274
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.